| 000 -LEADER |
|---|
| fixed length control field |
04371nam a22002777a 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
20241111104058.0 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
OCoLC |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20241111104516.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
241111b |||||||| |||| 00| 0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
978-1-4200-8422-1 (hardcover : alk. paper) |
| 040 ## - CATALOGING SOURCE |
|---|
| Transcribing agency |
ddc |
| 041 ## - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
English |
| 082 ## - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
338.476 151 ARN |
| 100 ## - MAIN ENTRY--PERSONAL NAME |
|---|
| Fuller form of name |
Renee J. G. Arnold |
| 222 ## - KEY TITLE |
|---|
| Key title |
Pharmacoeconomics From Theory to Practice |
| Qualifying information |
Amantadine approach Arnold assessment atopic dermatitis benefits CEA Cervarix cervical cancer Chapter CIN claims database clinical equivalence clinical trials CMA cohort compared considered cost-effectiveness analysis cost-utility cost-utility analysis costs CUA decision analysis decision tree decision-making discount rate DM programs drug discovery economic evaluation effectiveness estimate evidence example Figure Gardasil genital warts guidelines health economic health outcomes health plan healthcare hospital HPV vaccine HTA entity human papillomavirus ICER important incremental cost-effectiveness ratio interventions LMWH Markov model measure Medicare Medicine methodology methods NICE node non-inferiority options outpatient parameters particular patient satisfaction patient-reported outcomes payers PBAC perspective pharmaceutical pharmacoeconomic population potential practice probabilistic probability problem QALY QALYs gained QoL weights quality-adjusted range reference reimbursement relevant resource retrospective databases risk sensitivity analysis simulation specific strategies Table target testing therapeutic therapy tion treatment United utility validity variables warfarin Zanamivir |
| 240 ## - UNIFORM TITLE |
|---|
| Uniform title |
Pharmacoeconomics |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
Pharmacoeconomics |
| Remainder of title |
From Theory to Practice. |
| 246 ## - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
Pharmacoeconomics. |
| 247 ## - FORMER TITLE |
|---|
| Title |
Pharmacoeconomics. |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Place of publication, distribution, etc. |
Boca Raton, FL 33487-2742 | |
| Name of publisher, distributor, etc. |
Taylor and Francis Group, LLC | |
| Date of publication, distribution, etc. |
2010. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
259 Pages |
|
|---|
| Extent |
Includes bibliographical references and index. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
The pharmaceutical industry is almost boundless in its ability to supply new drug therapies, but how does one decide which are the best medicines to use within restricted budgets? With particular emphasis on modeling, methodologies, data sources, and application to real-world dilemmas, Pharmacoeconomics: From Theory to Practice provides an introduction to the major concepts and principles of pharmacoeconomics and cost-effectiveness analysis (CEA).<br/><br/>As a running theme, the book explores the collaboration among members of the pharmaceutical industry, academia, and government in the development of the human papillomavirus vaccine to demonstrate the full range of ethical and moral issues, as well as overall public health and commercial concerns that are often involved in decisions entailing CEA. Readers will learn about the international use of pharmacoeconomics in drug regulation, drug approval, and pricing, and the book provides examples of pharmacoeconomic models used to support these purposes in government, the pharmaceutical industry, and healthcare settings.<br/><br/>In this era of finite budgets, healthcare rationing, medication shortages, and the global aging and burgeoning of populations, numerous stakeholders in the healthcare arena must understand the basic principles of pharmacoeconomics and how these may be correctly applied to facilitate drug development, drug approval, rationing, patient segmentation, disease management, and pricing model development. Focusing on how to save money, not by restricting access to necessary services, but by using available resources more efficiently and rationally, this volume arms decision makers with the tools they need to make wise choices in an area where the stakes are so high.<br/><br/>Daniel E. Levy, editor of the Drug Discovery Series, is the founder of DEL BioPharma, a consulting service for drug discovery programs. He also maintains a blog that explores organic chemistry. |
| 600 ## - SUBJECT ADDED ENTRY--PERSONAL NAME |
|---|
| General subdivision |
Medical / General, Medical / Pharmacology, Science / Chemistry / General, Business, Business & Economics / Industries / Pharmaceutical & Biotechnology, Costs and cost analysis, Drugs - Cost effectiveness, Economics, Pharmaceutical, Electronic books, Outcome Assessment (Health Care) - economics, Pharmacy - Economic aspects, Decision making, Drugs -- Cost effectiveness, Pharmacy -- Economic aspect |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
ddc |
| Koha item type |
E-BOOKS |
| Suppress in OPAC |
|
